Lilly to buy immunology therapeutics company Dice Therapeutics for $2.4bn
Dice Therapeutics leverages the Delscape technology platform to develop novel oral therapeutic candidates, including oral IL-17 inhibitors to…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
21 Jun 23
Dice Therapeutics leverages the Delscape technology platform to develop novel oral therapeutic candidates, including oral IL-17 inhibitors to…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Jun 23
The site is expected to feature new manufacturing equipment to increase the company's lamination capacity for materials like…
21 Jun 23
The collaboration aims to facilitate the commercialisation of PharmaTher's Ketarx (racemic ketamine) products in the US
21 Jun 23
Taisho Pharmaceutical Named Commercial Partner for Biolinq’s Novel Biowearable Technology
20 Jun 23
CART-ddBCMA is a BCMA-specific CAR-modified T-cell therapy that uses the company’s BCMA-targeting binding domain for the treatment of…
19 Jun 23
Columvi (glofitamab-gxbm) is a CD20xCD3 T-cell-engaging bispecific antibody designed to target CD3 on the surface of T-cells and…
19 Jun 23
With this development, Prometheus now operates as a fully-owned subsidiary of Merck, and the common stock of Prometheus…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
16 Jun 23
Camzyos is already approved in the US, to treat adults with symptomatic New York Heart Association (NYHA) class…
16 Jun 23
According to the medical technology company, the trial is expected to use F-CD8 targeted imaging radiopharmaceutical to detect…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
16 Jun 23
Since its initial listing, Viva Biotech has successfully completed mergers and acquisitions, including SYNthesis and Langhua Pharmaceutical, resulting…